Purpose-Aggressive pancreatic cancer is commonly associated with a dense desmoplastic stroma, which forms a protective niche for cancer cells. The objective of the study was to determine the functions of tissue transglutaminase (TG2), a Ca 2+ -dependent enzyme which crosslinks proteins through transamidation and is abundantly expressed by pancreatic cancer cells in the pancreatic stroma.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is the fourth cause of cancer death (1) . With the currently available treatment, the majority of patients succumb to disease, resistance to chemotherapy and radiation having been implicated as pivotal obstacles (2) . A hallmark of pancreatic tumors is the dense desmoplastic stroma (DS) composed of myofibroblasts and stellate cells which secrete collagens and other matrix proteins that serve as a scaffold on which tumor cells proliferate (3) (4) (5) . These stromal components are highly responsive to cytokines (TGF-β) and growth factors (PDGFs, FGFs, sonic hedgehog) abundantly secreted in the tumor microenvironment (TME) (4-7). The stroma, believed to protect PDA cells from environmental stress, is hypovascular, hypoxic, and presumably less permeable to chemotherapy (4, 5, 8) . In support of the latter concept, a recent study using clinical PDA specimens demonstrated that the delivery of gemcitabine into human pancreatic tumors is highly heterogenous and strongly correlated with the existing stromal reaction (9, 10) . However, two other recent reports have suggested that some components of the stroma may play a reverse role, by restraining cancer cell invasion and preventing tumor metastasis (11, 12) . The latter studies used analyses in genetically engineered PDA mouse models that may not faithfully mirror the desmoplastic reaction of human tumors. The conflicting outcomes of previous studies (8, 12) coupled with the continued lack of success treating this recalcitrant disease, underscore the complex interplay between the diverse components of pancreatic tumors and the inherent limitations of existing experimental models to study and replicate the diverse traits of the human disease (13) . The data presented here highlight the crosstalk between cancer and stromal cells mediated by tissue transglutaminase (TG2) and the significance of the crosslinking reaction mediated by this enzyme in the matrix to PDA progression.
TG2 is a TGF-β inducible protein (14) secreted in the extracellular milieu which mediates the transfer of acyl groups between glutamine and lysine residues, causing protein crosslinking (15) . Highly expressed in pancreatic cancer cells and tumors, TG2 was reported to activate NF-κB orchestrated survival mechanisms and to contribute to chemotherapy resistance, independently of its enzymatic function (16, 17) . Whether and how TG2 promotes pancreatic tumor growth remains not clear. Based on the knowledge that the enzyme is secreted and acts as a potent crosslinking factor for collagens and matrix proteins (18) , and that the enzymatic function of TG2 is augmented in the extracellular matrix (ECM) by factors such as hypoxia and tissue injury (19) , we hypothesized that TG2 secreted by targeting TG2 (shTG2) in the presence of polybrene (8μg/mL). As control (shCtrl), cells were transduced with MISSION ® pLKO.1-puro Empty Vector control Transfection Particles (Sigma). Both shCtrl and shTG2 particles were transduced at 2.5 multiplicity of infection. Pooled stable clones were collected after selection with puromycin at 1 μg/ml concentration, and TG2 knockdown was verified by western blotting. Transient transfection of short interfering RNA (siRNA) used sequences targeting YAP and TAZ (Santa Cruz) and Lipofectamine ® 3000 (Life technologies, Carlsbad, CA). siGENOME ™ Control Pool (Dharmacon, Lafayette, CO) was use as control.
Western Blot Analysis followed a standard protocol (see SM).
Orthotopic Pancreatic Xenografts 1.5×10 5 AsPC1 and Panc1 cells, stably transfected with shTG2 or shCtrl were injected into the pancreatic tail of 7-8 weeks old female nude mice (Harlan, Indianapolis, IN) using a 27.5 gauge needle under isoflurane anesthesia. Three (Panc1 cells) or 4 weeks (AsPC1 cells) after injection, mice were euthanized and tumors were weighted and measured. Tumor volumes were calculated as 4/3*π*(L/2)*(W/2)*(H/2); where L is length, W, width, and H, height. Metastatic implants were counted. Animal experiments were approved by the IU Animal Care and Use Committee, in compliance with federal regulations.
Immunofluorescence (IF) used antibodies for TG2 (Neomarkers), α-SMA (Sigma), collagen 1 (Abcam), and YAP/TAZ (Cell Signaling). To detect matrix-bound TG2, cells were not permeabilized before incubation with the TG2 antibody, as previously described (23) . Procedures are detailed in SM.
Proliferation Assays were performed as described in SM.
Reporter Assay
To measure YAP/TAZ transcriptional activity, PDA cells were transfected with pGal4-TEAD4, pGal4-Luciferase, and pTK-Renilla at a ratio of 1:10:1 using DreamFect (Oz Biosciences, Inc., San Diego, CA). Plasmids were a gift from Dr. Clark Wells (IUSCC) (24) . The Dual-Luciferase ® Assay System kit (Promega, Madison, WI) determined TEAD4 reporter activity after 48 hours of transfection. To control for transfection efficiency, the luciferase activity was normalized to renilla.
Picrosirius Red (PSR) Staining
Paraffin-embedded slides were incubated with PSR solution containing 0.1% of Direct red 80 powder (Sigma) dissolved in picric acid (Sigma) for 1 hour. Nuclei were counterstained with hematoxylin. The slides were washed in 0.5% glacial acetic acid and dehydrated in ethanol and xylene. Imaging with circular polarizing light used an inverted Nikon Diaphot 200 microscope (Nikon, Melville, NY). The proportion of differently colored collagen fibers was quantified with MetaMorph (Molecular Devices, see SM) (26) .
Soluble Collagen Assay
Soluble collagen in xenografts (n=6 per group) was determined by using the Sircol ™ Soluble Collagen Assay kit (Biocolor Life Science Assays, Northern Ireland, see SM).
TG2 Activity
PDA cells and fibroblasts were incubated with 500 μM 5-(Biotinamido) pentylamine (5-BP) (ThermoScientific) for 1 hour at 37°C. After fixing in methanol, slides were incubated with Alexa Fluor ® 647 streptavidin (Life Technologies) for 1 hour. To assay in situ activity of TG2 in tumor tissue, 10 μm cryosections were incubated at 37°C in a buffer containing 5 mM CaCl 2 , 100 mM Tris-HCl (pH 8.0), in the presence or absence of 1 mM DTT, and 0.001 mM T26 or T26QN (negative control), as described (27) (28) (29) . As another negative control, 5 mM EDTA was added to the buffer. Imaging used a LSM 510 META confocal microscope (Carl Zeiss, Inc.) under UV excitation.
Statistical analysis
Student's t test compared measurements. P < 0.05 was significant.
Results

TG2 is abundantly expressed and enzymatically active in PDA cells and stroma
We used immunohistochemistry (IHC) to measure TG2 expression and cellular localization in PDA specimens and in normal pancreas. Patient characteristics are presented in SM (Supplementary Table 1 ). No immunostaining was recorded in the stroma of normal pancreas (n=3), and faint (1+) staining was noted in normal ducts. In contrast, strong (2+ to 3+) TG2 cytoplasmic immunostaining was recorded in 36 out of 52 (69%) PDA specimens, supporting that TG2 expression is increased in PDA compared to normal duct epithelium. TG2 immunostaining was also recorded in the stroma of 44 out of 52 specimens (84%, Figure 1A ), involving both the cellular (fibroblasts) and extracellular compartments. To determine whether TG2 was enzymatically active in the stroma, 20 additional tumors identified through the IUSCC Tissue Bank as PDA specimens associated with significant desmoplasia were stained for TG2 and for isopeptide, a covalent bond resulting from TG2 mediated transamidation. Concordant strong (2+ to 3+) TG2 and isopeptide staining were recorded in 19 out of 20 specimens ( Figure 1A ), supporting that TG2 is expressed and active in the pancreatic DS. Isopeptide staining was detectable in the matrix and the basal membrane.
TG2 expression levels in cell lysates and CM from PDA, HPNE, stellate cells, and fibroblasts were examined by using western blotting. Abundant TG2 expression was detected in BxPC3 and AsPC1 cells and in the conditioned media (CM), confirming that it is secreted by PDA cells (Figures 1B). TG2 expression was detectable in HPNE cells but lower than in most cancer cell lines. Immunofluorescence (IF) determined TG2 cellular localization and enzymatic activity by measuring incorporation of 5-(Biotinamido) pentylamine (5-BP) and FITC-labeled T26 peptide, known TG2 substrates ( Figure 1C and Supplementary Figure 1) . TG2 was expressed in the cytosol and the plasma membrane of AsPC1 and Panc1 cells, and its enzymatic activity was detectable in the cytoplasm of both cell types. In contrast, TG2 was present, but was enzymatically inactive in fibroblasts ( Figure 1C ) and in LP9 normal mesothelial cells (Supplementary Figure 1B) , suggesting that the enzymatic activity may be differentially regulated in cancer vs. normal cells. Specificity is supported by lack of IF signal when cells were incubated with the mutant T26QN peptide (not a TG2 substrate) or in the presence of EDTA, which chelates Ca 2+ (Supplementary Figure 1A) . In addition, extracellular TG2 was detectable in the matrix deposited by AsPC1, BxPC3 and Panc1 cells (Supplementary Figure 2) , supporting the concept that PDA cells secrete TG2 into the ECM.
TG2 knockdown inhibits PDA tumor growth in vivo
To proceed with functional studies, TG2 was knocked down in AsPC1 and Panc1 cells by stably transducing shRNA targeting TG2 (shTG2). TG2 protein and mRNA expression levels were significantly downregulated in shTG2 transduced cells compared to cells transduced with scrambled shRNA (shCtrl, Figure 1D ). TG2 secretion in the CM was also decreased in shTG2 compared to shCtrl transduced PDA cells ( Figure 1D , right panel). However, in vitro, no significant differences in the proliferation and ability to form clones between PDA cells +/−shTG2 were observed (Supplementary Figure 3) , suggesting that any effects of TG2 on tumor growth are not explained by direct effect on cancer cells.
To measure the effects of TG2 on tumor formation and progression, orthotopic pancreatic xenografts derived from AsPC1 and Panc1 cells in which TG2 was stably knocked down were used. Average tumor volume and weight were significantly decreased in xenografts derived from AsPC1+shTG2 compared to AsPC1+shCtrl cells ( Figure 2A , left and middle panels). There was no significant difference in the number of macro-metastases between groups ( Figure 2A , right panel). Stable knockdown of TG2 in AsPC1+shTG2 xenografts compared to controls was confirmed by IHC and was quantified by comparing H scores (see SM, Figure 2B ). Similar decrease in average tumor volume and weight was observed in Panc1+shTG2 vs. Panc1+shCtrl xenografts ( Figure 2C , left and middle panels). The number of macro-metastases was significantly decreased in Panc1+shTG2 tumor bearing mice compared to controls ( Figure 2C , right panel). Stable knockdown of TG2 was confirmed by IHC ( Figure 2D ). Together, these data demonstrate that TG2 expression levels in PDA cells strongly correlate with in vivo tumor growth.
TG2 is enzymatically active and crosslinks collagen in PDA tumors
Under normal physiological conditions, TG2 is enzymatically inactive in vitro and in vivo. Various stressors such as injury or hypoxia, are required to activate TG2 (30) . To determine Lee et whether TG2 is activated in the pancreatic TME, we measured incorporation of the FITClabeled T26 peptide, which is specifically crosslinked to ECM proteins by TG2 (29) . Enzymatically active TG2 was detectable both intra-and extra-cellularly in AsPC1 and Panc1 xenograft sections ( Figure 3A) , suggesting that the enzyme is active in the pancreatic milieu. Incubation with the T26 peptide in the presence of EDTA and with the mutant T26QN peptide, which is not a TG2 substrate, were used as negative controls to prove specificity. TG2 activity was detectable even in the absence of DTT, a known TG2 activator (31) (Supplementary Figure 4) , supporting that the enzyme is activated in situ.
One of the known TG2 substrates is collagen 1, abundant in the pancreatic DS. PSR staining was used to determine whether collagen 1 was crosslinked by TG2 in the pancreatic TME. Birefringence of PSR staining under polarizing microscope is highly specific for collagen fibers, which appear red, orange, yellow, or green in order of decreasing thickness (26) . Collagen fibers stained mostly bright orange, red, and yellow in AsPC1+shCtrl tumors, while fibers were mostly green and yellow in AsPC1+shTG2 tumors (Figures 3B left and middle panels), suggesting that collagen fibers are thicker in TG2 expressing tumors. Moreover, the area of birefringence corresponding to collagen was more extensive in AsPC1+shCtrl compared to AsPC1+shTG2 xenografts ( Figure 3B , right panel), suggesting increased collagen deposition in TG2 expressing tumors, most collagen being deposited around ducts and at the edge of tumors. To verify that this correlation is relevant to human pancreatic tumors, PSR staining of TG2-high and TG2-low human tumors was carried out (n=6 per group). TG2 expression levels strongly correlated with the percentage of crosslinked collagen (p < 0.001, Figure 3C ).
Additionally, the sircol and the hydroxyproline assays were used to measure soluble and total collagen, respectively, in protein extracts from xenografts expressing TG2 or not. The amount of soluble collagen was increased in AsPC1+shTG2 compared to AsPC1+shCtrl tumors ( Figure 3D , left panel) and in Panc1+shTG2 compared to Panc1+shCtrl xenografts ( Figure 3D , right panel), while total collagen content was similar (Supplementary Figure 5) . Collectively, these data suggest that TG2 secreted from PDA cells promotes collagen crosslinking in the pancreatic stroma.
TG2-mediated crosslinked collagen and TG2 expressing PDA cells promote the growth and activation of fibroblasts
We next determined the functional significance of native and TG2-crosslinked collagen to the proliferation of fibroblasts and cancer cells. The proliferation of NHF544 fibroblasts was increased on collagen coated compared to uncoated plates ( Figure 4A , left-upper panel) and on TG2-crosslinked collagen compared to native collagen ( Figure 4A , left-lower panel), supporting that collagen and crosslinked collagen in the matrix promote fibroblast proliferation.
Next, we studied the influence of TG2 secreted by cancer cells on stromal cell proliferation. Direct co-culture of TG2 expressing AsPC1 cells significantly promoted GFP-labeled fibroblast (GFP-HNDF) proliferation over a 14-day period compared to co-culture of fibroblasts with AsPC1+shTG2 cells ( Figure 4A , right panel). Fibroblast proliferation in coculture with cancer cells expressing and secreting low levels of TG2 (AsPC1+shTG2) was not different from proliferation of fibroblast cultured alone, supporting that secretion of TG2 in co-culture models augments the fibrotic response. However, in the absence of co-cultured PDA cells, addition of recombinant TG2 to the growth media did not alter fibroblast or stellate cell proliferation (Supplementary Figure 6) , suggesting that TG2 acts in concert with other factors secreted in the matrix.
To measure fibroblast activation in the presence of cancer cells, expression of α-smooth muscle actin (α-SMA) was measured by IF. Co-culture of NHF544 cells with AsPC1 and Panc1 cells induced expression of αSMA ( Figure 4B , left panels). To determine whether TG2 secreted by PDA cells contributes to fibroblast activation, NHF544 cells were cocultured with PDA cells +/−shTG2, and IF staining measured collagen deposition. Increased collagen 1 staining was observed in NHF544 fibroblasts co-cultured with AsPC1 and Panc1 control cells, compared to fibroblasts co-cultured with AsPC1+shTG2 and Panc1+shTG2 cells ( Figure 4B , right panels). Likewise, in tumors, the number of α-SMA expressing (activated) myofibroblasts was increased in AsPC1+shCtrl compared to AsPC1+shTG2 xenografts ( Figure 4C ). Collectively, these data show that in the pancreatic TME, TG2 secreting PDA cells promote the growth, activation, and collagen deposition by myofibroblasts.
We next tested whether these stromal alterations conversely regulate the growth of PDA cells. Proliferation of AsPC1 and Panc1 cells was promoted when cells were cultured on collagen coated vs. uncoated plates ( Figure 4D , upper panel) and on a feeder layer of hPSCs vs. uncoated plates ( Figure 4D , lower panel). Taken together, these results demonstrate that PDA cells secreting TG2 in the tumor milieu promote fibroblast activation and proliferation as well as collagen crosslinking, leading to stromal alterations, which in turn promote tumor growth.
Matrix induced YAP/TAZ activation promotes PDA cell proliferation
As the pancreatic stroma becomes infiltrated by collagen and fibroblasts, its stiffness increases (32) . One of the mechanisms activated by the physical properties of the ECM is the YAP/TAZ pathway (33) , which regulates cancer cell growth. We measured activation of the pathway by IF staining for the two nuclear factors in PDA cells plated on collagen vs. uncoated plates. Increased nuclear YAP/TAZ staining was observed in Panc1 and AsPC1 cells on collagen ( Figure 5A ). Western blotting showed decreased levels of phospho-YAP (p-Yap, inactive) and increased ratio of total-YAP/p-YAP were recorded in PDA cells plated on collagen-coated vs. uncoated plates ( Figure 5A , right panel), indicating YAP activation by the collagen matrix.
Next, IF staining determined the effect of TG2 on YAP/TAZ activation in PDA cells. Increased nuclear localization was recorded in TG2 expressing control Panc1 and AsPC1 cells compared to PDA cells transduced with shTG2 ( Figure 5B ). Decreased level of p-YAP and increased ratio of total-YAP/p-YAP were observed in Panc1+shCtrl compared to Panc1+shTG2 cells ( Figure 5B , right panel). We next measured the transcriptional activity of YAP in Panc1 cells plated on collagen by using the TEAD4 reporter assay and by measuring the mRNA levels for CTGF, a known YAP/TAZ target gene. TEAD4 activity ( Figure 5C , upper panel) and CTGF mRNA levels ( Figure 5C , lower panel) were increased in Panc1+shCtrl compared to Panc1+shTG2 cells, confirming activation of the pathway in TG2 expressing cells.
To determine the significance of YAP/TAZ to PDA cell proliferation, transient siRNA transfection targeting both transcription factors was employed. YAP and TAZ knockdown by siRNA confirmed by western blotting ( Figure 5D , upper panel) caused decreased proliferation of AsPC1 and Panc1 cells grown on collagen ( Figure 5D, lower panel) . Collectively, these data suggest that the transcription factors YAP and TAZ are activated in TG2 expressing PDA cells and outline a new mechanism by which cancer cell proliferation is modulated by TG2 through signals reflected from the tumor into the surrounding stroma ( Figure 6 ).
Discussion
Our findings outline how changes in the pancreatic cancer stroma induced by TG2 secreted from PDA cells alter tumor growth. While overexpression of TG2 in epithelial cancers (34, 35) including in pancreatic cancer (36, 37) has been previously reported, and its direct effects on cellular oncogenic signaling have been dissected (37, 38) , this is the first report describing the effects of TG2 on the pancreatic TME, and its subsequent consequences on cancer cell proliferation and tumor growth. We demonstrate that TG2 expressing PDA cells form larger pancreatic tumors, enriched in thick collagen fibers and in myofibroblasts. The dense stroma of TG2 expressing tumors conveys signals leading to YAP/TAZ activation in cancer cells promoting cell proliferation and tumor growth. This report has several important consequences.
First, we demonstrate that TG2 knockdown in pancreatic cancer cells inhibited tumor growth. This effect was more pronounced in Panc1 compared to AsPC1 cells, possibly because of the shorter doubling times of Panc1 cells, which are more aggressive and semimesenchymal. Interestingly, the smaller tumor volumes were not accounted for by decreased proliferation or clonogenic potential of the PDA cells, but by substantial stromal alterations. A previous study using siRNA targeting TG2 delivered as liposomes into the peritoneal cavity noted inhibition of pancreatic tumor growth along with decreased tumor vascularity and decreased cancer cell proliferation (36) . In that study, TG2 knockdown affected all TG2 expressing cells exposed to the carrier liposomes. It is, therefore, possible that TG2 knockdown in endothelial cells led to the anti-angiogenic effect reported there and the subsequent inhibition of cell proliferation (36) . Contrasting to that study and consistent with TG2 knockdown restricted to PDA cells in our model, we did not observe changes in multivessel density between tumors expressing TG2 or not (not shown). However, we report a significant decrease in the number of activated myofibroblasts and thick collagen fibers in tumors derived from shTG2 transduces cells. We show that these stromal alterations directly affect proliferation of fibroblasts and cancer cells. The protective role of the pancreatic stroma to cancer cells has been previously recognized and linked to the resistance of pancreatic tumors to chemo and radiotherapy (39) (40) (41) . Our data implicate for the first time TG2 as a modulator of the pancreatic TME through its protein crosslinking properties.
Second, we report that TG2 is enzymatically active in PDA cells and in the matrix where it crosslinks collagen, and possibly other ECM substrates. It is known that the functions of TG2 are tightly controlled by environmental factors, which cause allosteric structural changes and alter the accessibility of the catalytic site. High Ca 2+ concentrations in the ECM allow the protein to adopt an open conformation that exposes the enzymatic core, while high intracellular GTP forces a closed, enzymatically inactive structure (19) . It is, therefore, accepted that TG2 is enzymatically inactive in the intracellular environment, under normal physiological conditions, as we have also observed here by analyzing human fibroblasts and mesothelial LP9 cells. However, crosslinking activity was detectable in PDA cells and their matrix as assessed in vitro and in vivo, suggesting that the enzyme is activated in transformed cells and in the pancreatic matrix. While the factors causing TG2 activation in this context remain unknown, it is tempting to speculate that hypoxia or other types of tissue injury inflicted by tumorigenesis may be inducing transglutaminase activity in vivo (30, 42) . The involvement of metabolic or physical factors that could be expressed or function differently in transformed vs. normal cells (e.g. oxidative stress, calcium homeostasis) cannot be excluded. Interestingly, a previous report suggested that Ikβα, the NF-κB inhibitory subunit, is a direct substrate of TG2 in PDA cells (16) , although direct evidence of TGase activity was not provided.
We also show that collagen 1 was crosslinked by TG2 in the pancreatic milieu leading to formation of a dense matrix that stimulated the growth of fibroblasts and cancer cells. Increased collagen deposition was noted in fibroblasts co-cultured with TG2 expressing PDA cells. Our findings are consistent with a previous report demonstrating that collagen crosslinked by TG2 stimulated the proliferation of dermal fibroblasts (25) and with studies demonstrating the involvement of TG2 in wound healing and in pathologic fibrotic responses in the lung or liver (15, (43) (44) (45) (46) . We suspect that the enzyme has other substrates in the pancreatic ECM and that their modifications through crosslinking could contribute to the distinct architecture of the DS, which in turn fosters tumor progression.
Third, we link here for the first time TG2 to activation of the transcriptional regulators, YAP and TAZ, in cancer cells. This pathway, strongly implicated in cell survival and proliferation and activated in epithelial cancers (47, 48) , is known to be regulated by the physical properties of the ECM and to translate mechanical cues into relevant biological signals (33) . Recent reports have implicated YAP signaling in pancreatic tumor progression downstream of mutant Ras or independent of it (49, 50) . We propose that the pancreatic matrix rendered denser by TG2 through collagen crosslinking and stimulation of a fibrotic response, provides positive proliferative feedback to the cancer cells by stimulating YAP/TAZ signaling. Interestingly, TG2 expression levels did not alter cancer cell proliferation in the absence of the matrix. However, we cannot exclude that signals other than tissue stiffness, directly modulated by TG2 or by the matrix, contribute to YAP activation in this context.
These observations led us to posit that the stimulatory growth signals conveyed by TG2 require the stroma, which "deflects" mechanical or biological cues from the tumor milieu into an active oncogenic program. In all, our findings support the involvement of enzymatically active TG2 in the progression of PDA and future studies targeting the crosslinking activity of TG2 to disrupt tumor progression.
Translational Relevance
Aggressive and chemotherapy-resistant pancreatic cancer is commonly associated with a dense stroma, which forms a protective niche for cancer cells. We hypothesized that tissue transglutaminase (TG2), a transamidating enzyme secreted by pancreatic cancer cells, promotes pancreatic cancer progression by protein crosslinking in the stroma. Our data present the first evidence that TG2 is abundantly secreted and enzymatically active in the pancreatic tumor milieu where it crosslinks collagen and stimulates fibroblast proliferation. We demonstrate that TG2 orchestrates the development of a characteristic fibrotic inflammatory reaction that enables tumor growth. Our data point to a novel mechanism, involving the tumor microenvironment by which TG2 promotes pancreatic tumor progression. The findings have important consequences for developing strategies to block TG2 enzymatic activity and control pancreatic cancer growth. Proposed mechanism by which TG2 promotes tumor growth. 
